PNEUMOCYSTIS DNA PCR TEST

  • Test Code

    402

  • CPT Code

    87798 x1

  • Clinical Significance

    Pneumocystis jirovecii (formerly known as Pneumocystis carinii) is an opportunistic fungal pathogen that causes life-threatening Pneumocystis pneumonia (PCP) in immunocompromised patients, including those with HIV. Patients may present with non-specific symptoms such as fever, cough, shortness of breath, and fatigue. Pneumocystis cannot be cultured in vitro and has classically been diagnosed based upon clinical symptoms and radiographic findings with confirmation via microscopic visualization of stained organisms which has lower sensitivity that is reliant upon reader expertise. This real-time PCR assay provides 96.7% sensitivity and 100% specificity, with a limit of detection of 4.6 copies/µL for detection of Pneumocystis from bronchoalveolar lavage (BAL) fluid.

  • Methodology

    Qualitative Real-Time PCR (Polymerase Chain Reaction) on the Roche Lightcycler® 480 II

  • Limitations

    No cross-reacting organisms or interfering substances were identified during validation.

  • Specimen Collection

    BAL, sputum, tracheal aspirate*, or bronchial wash* in a sterile leak-proof container.

    * Reported with a rare specimen comment applied.

  • Minimum Specimen Requirements

    BAL, sputum, tracheal aspirate*, or bronchial wash* = 0.5 mL

    * Reported with a rare specimen comment applied.

  • Specimen Stability

    BAL

    • Room Temperature/Ambient: 30 days
    • Refrigerated: 30 days
    • Frozen: 30 days

    Sputum

    • Refrigerated: 14 days
    • Frozen: 14 days
  • Specimen Rejection
    • CSF and all other non-respiratory samples.
    • Two unique patient identifiers are required on the specimen container.
    • Specimens with particulate matter or viscosity that would not allow the specimen to be pipetted will be rejected.
  • Transport Temperature
    • Refrigerated with ice packs
    • Frozen
  • Shipping

    Ship on dry ice to arrive Monday-Friday using a next day delivery service. Frozen ice packs may be substituted if sample is shipped the day of collection.

  • Turnaround Time

    24-48 hours, Monday through Friday

  • Reference Range

    Not detected

  • Interpretative Information

    A Detected (positive) result indicates presence of Pneumocystis jirovecii DNA. It does not rule out the presence of or co-infection with other organisms, and Pneumocystis jirovecii may not be the causative agent of the clinical symptoms.

    A Not Detected (negative) result indicates that Pneumocystis jirovecii DNA was not present at a level above the limit of detection. It does not exclude the presence of Pneumocystis jirovecii.

    Results should be correlated with clinical presentation and history.

  • Additional Information

    This test was developed, and its analytical performance characteristics determined by MiraVista Diagnostics. It has not been cleared or approved by the FDA; however, FDA clearance or approval is not currently required for clinical use. The results are not intended to be used as the sole means for clinical diagnosis or patient management decisions.

* New positives may require confirmation.

** Turnaround times are provided as ranges, and may vary depending on daily testing volumes and specimen type.

*** Test set-up: Samples received by 10:30 AM are eligible for same-day testing. Same-day testing is not guaranteed and may vary based on daily test volume, sample receipt time, testing schedules, and sample type. Some samples may require pretreatment and/or confirmatory testing, which can extend turnaround time (TAT).

**** Two unique patient identifiers are required on specimen containers. 

***** Specimens with particulate matter or viscosity that would not allow the specimen to be pipetted will be rejected.

CONTACT US

Only Available at MiraVista Diagnostics: MycoMEIA® Aspergillus Galf Urine EIA
MiraVista Diagnostics now offers MycoMEIA® Aspergillus Galf Urine EIA, a urine-based antigen assay that complements serum galactomannan (GM) testing and may improve diagnostic confidence for invasive aspergillosis (IA).

X